Fredun Pharmaceuticals Intrinsic Value
FREDUN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1758.24 | ₹1406.59 - ₹2109.89 | +14.4% | EPS: ₹79.92, Sector P/E: 22x |
| Book Value Method | asset | ₹564.00 | ₹507.60 - ₹620.40 | -63.3% | Book Value/Share: ₹282.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2304.00 | ₹2073.60 - ₹2534.40 | +50.0% | Revenue/Share: ₹1152.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1680.00 | ₹1512.00 - ₹1848.00 | +9.4% | EBITDA: ₹84.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹511.49 | ₹460.34 - ₹562.64 | -66.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1234.76 | ₹1111.28 - ₹1358.24 | -19.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1152.00 | ₹1036.80 - ₹1267.20 | -25.0% | ROE: 25.5%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹564.00 | ₹507.60 - ₹620.40 | -63.3% | EPS: ₹79.92, BVPS: ₹282.00 |
Want to compare with current market value? Check FREDUN share price latest .
Valuation Comparison Chart
FREDUN Intrinsic Value Analysis
What is the intrinsic value of FREDUN?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Fredun Pharmaceuticals (FREDUN) is ₹1234.76 (median value). With the current market price of ₹1536.30, this represents a -19.6% variance from our estimated fair value.
The valuation range spans from ₹511.49 to ₹2304.00, indicating ₹511.49 - ₹2304.00.
Is FREDUN undervalued or overvalued?
Based on our multi-method analysis, Fredun Pharmaceuticals (FREDUN) appears to be trading above median value by approximately 19.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.78 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 3.45 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 25.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.18x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Fredun Pharmaceuticals
Additional stock information and data for FREDUN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹0 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-14 Cr | ₹-19 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2020 | ₹-11 Cr | ₹-12 Cr | Negative Cash Flow | 3/10 |